Posfrea (Palonosetron HCl) Patent Expiration, LOE Window & CMS Spending

Posfrea (Palonosetron HCl) by Avyxa Holdings: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $83K 2024 CMS Part D & Medicaid spend, and $580 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAvyxa Holdings
FDA Application & PathwayN203050 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$83K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$83K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($580 intro WAC)